MG-132 化学構造
分子量: 475.62

高品質保証

文献中の引用(42)

カスタマーフィードバック(9)

Quality Control & MSDS

製品説明

  • Compare Proteasome Inhibitors
    Proteasome製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 MG-132は、100nMのIC50によるプロテアソームの強力な阻害剤です。
ターゲット

Proteasome

IC50

100 nM [1]

In vitro試験 MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cells M2XLbWZ2dmO2aX;uJGF{e2G7 NUDCRmRIOjVizszN NFe2[WtFVVOR MV\Jcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4yKM7:TR?= M3OyO|I1Pjl5NEm2
HL-60 M4HpOWN6fG:2b4jpZ{BCe3OjeR?= M2TpTVQxKM7:TR?= MWS0PEBp MnvySG1UVw>? MYjJR|UxRDFyIN88US=> NYLYd45MOjR4OUe0PVY>
SMMC-7721 M3XKfmN6fG:2b4jpZ{BCe3OjeR?= MV:0NEDPxE1? M{LxS|Q5KGh? M2e5WWROW09? NHXY[3hKSzVyPUeuNUDPxE1? NIDEVXQzPDZ7N{S5Oi=>
A-549 NELOenhEgXSxdH;4bYMhSXO|YYm= Mn7hOFAh|ryP M2T3U|Q5KGh? M4DVUmROW09? M2\nXGlEPTB:MUCg{txO NFvxZnIzPDZ7N{S5Oi=>
MCF-7 NUT6TGNTS3m2b4TvfIlkKEG|c3H5 NWDZbmJ1PDBizszN MmLNOFghcA>? NX;RWldKTE2VTx?= M3zVTmlEPTB;Nz6zJO69VQ>? NH;VcmYzPDZ7N{S5Oi=>
SW-480 MWjDfZRwfG:6aXOgRZN{[Xl? Mk\ROFAh|ryP NGHMdWQ1QCCq NFLleG9FVVOR NY\WPVFUUUN3ME20JO69VQ>? MmW2NlQ3QTd2OU[=
NCI-H929 NF;rOpFEgXSxdH;4bYMhSXO|YYm= MoXHNUDPxE1? M{DZWFczKGh? MnLCSG1UVw>? NG\YRVlKSzVyPUCuNVch|ryP MW[yOFYzPTB6OB?=
293T NWSzb4xHS3m2b4TvfIlkKEG|c3H5 NUTaNpBFOTBizszN Mn:xO|IhcA>? NGnCSHZFVVOR NYfuZXFSUUN3MEyyJO69VQ>? MVWyOFYzPTB6OB?=
293T Mn;GSpVv[3Srb36gRZN{[Xl? NEf0R2QyOCEQvF2= NXXOPFVOOjRiaB?= MnvrSG1UVw>? NWLqfIc4VW:mZYLheIVtgSCrbnT1Z4V{KGinYYStd4hw[2tiIB?= MkHDNlQ3OjVyOEi=
HeLa MkHaT4lv[XOnIFHzd4F6 MUKxNEDPxE1? NI[0SXgyKGh? NVjufINRTE2VTx?= NWHId4N2UW6mdXPld{BRSVKSIHPs[YF3[WenIHL5JIlvcGmkaYTpcocheHKxc3Xhd49u\SCjY4Tpeol1gQ>? MX6yOFMzOTh|Mx?=
MDA-MB-231 M2LvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDjNUDPxE1? NYrBcGI4PzJiaB?= NITnXm9FVVOR M1;IU2lEPTB;MD6xPEDPxE1? MYiyOFE2OzJyNh?=
MCF-7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H0UFEh|ryP M1;vUFczKGh? M{TCSmROW09? M2P5UmlEPTB;MD6xN{DPxE1? MmCwNlQyPTN{ME[=
MCF10A NGXld2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSxJO69VQ>? MXK3NkBp NEfkWnBFVVOR NUjucItUUUN3ME2wMlI6KM7:TR?= NFrOc3MzPDF3M{KwOi=>
HEK-293 NIjEZ4pMcW6jc3WgRZN{[Xl? MknwNkBidmRiMkCg{txO M1zqUlIhcA>? NED3Z3RFVVOR NUHVXZVmUW6qaXLpeJMhS2iWLVygZYN1cX[rdImge4l1cCCLQ{WwJI9nKDlibl2g MYqyN|U1ODd7MB?=
Calu6 M36wZ2Z2dmO2aX;uJGF{e2G7 NXnZNXBlOTBizszN NFv1e4syQCCq MomzSG1UVw>? M{m0SnNq\26rZnnjZY51dHliYXPjeY12dGG2ZYOg[pJifGG6aX6gdJJm[3W{c3;y NWjUfodKOjN3ME[0PFY>
IFN-gamma-induced RAW264.7 MU\GeY5kfGmxbjDBd5NigQ>? NHOzNVJFVVOR Mmi5TY5pcWKrdIOgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvODd5IN88US=> NVztUHRROjJ{N{eyO|c>
IPC227F MlXuR5l1d3SxeHnjJGF{e2G7 MnrGNUDPxE1? NVu1bmJqPDhiaB?= MnTpSG1UVw>? NXq2OZBJUUN3ME2wMlA4PyEQvF2= Mm\ZNlE6OjR3Mki=
Hepa-1c1c7 MX;GeY5kfGmxbjDBd5NigQ>? MXyyOUDPxE1? MYi2JIg> NX3GfnJXTE2VTx?= MUPJcoNz\WG|ZYOgUpJnOiCycn;0[YlvKGyndnXs Ml3wNlA{QTJ3NES=
COS-7 MYPDfZRwfG:6aXOgRZN{[Xl? MW[xNEDPxE1? M{HBUmROW09? MV7JR|UxRDFyIN88US=> M2[zOVE5ODh6MEm3
HuH-7 NV3xelZUS3m2b4TvfIlkKEG|c3H5 M17q[VExKM7:TR?= NUnjO4p6TE2VTx?= MkntTWM2ODxzMDFOwG0> NFnsUnkyQDB6OEC5Oy=>
OCI-Ly3 NHzpZldHfW6ldHnvckBCe3OjeR?= MkmxNVAh|ryPwrC= NHfQNlI1KGh? MoHySG1UVw>? NIXubI5KdmS3Y3XzJIh2dWGwIFnrZZBx[UKjbIDoZUB{fGGkaXzpfoF1cW:wIIfpeIghTUN3MDDv[kAyKM7:TR?= M36zNVE5ODJ2MUGz
A2780 cDDP M4m2eGFxd3C2b4Ppd{BCe3OjeR?= M2W0SFI1KGh? NVK2eFdtTE2VTx?= MoLCTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6qaXLpeIlv\yCSVFXOJIRm\3KjZHH0bY9v M1TvcVE4Pjh2MEG4
LPS-stimulated RAW264.7 cells MXfGeY5kfGmxbjDBd5NigQ>? NX\HZWE{TE2VTx?= NYW0TIFiUW6qaXLpeJMhVkZva3HwdIFDKESQQTDibY5lcW6p NX;VZYh3OTd2MEeyO|c>
PC12 NV7POZM1TnWwY4Tpc44hSXO|YYm= M3;sWFExOCEQvF5CpC=> NWLvXmwzOjRiaB?= NFTFPXBFVVOR NX;FbZVNUW6qaXLpeJMhPi2RSFTBMUBidmRiSELPNk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? M{HlUFE4OTV6NEW0
PC3 NYXTbVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jDSVIxKM7:TR?= MXG0PEBp NWTnUpVHTE2VTx?= Mn\RTWM2OD1yLk[g{txO NFvOWIoyPjZ6NkWzOy=>
LP-1 Ml3DRZBweHSxc3nzJGF{e2G7 NXLPT2FTOzByIH7N MYSyOEBp Ml\3SG1UVw>? NXraWJhmUW6mdXPld{BieG:ydH;zbZMh[nliaX7jdoVie2mwZzDjcIVifmWmIGDBVnAhdGW4ZXygZY5lKHKnZIXjbY5oKE2lbD2xJJBzd3SnaX6gcIV3\Wx? NFnXZ2EyPTl3OEW4PS=>
ES6 NUPnS41ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fBSWlEPTB;MD6wNVMxPiEQvF2= MVjTRW5ITVJ?
A101D MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Hzb2lEPTB;MD6wN|I4QSEQvF2= MVnTRW5ITVJ?
OCUB-M MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMEO3N|ch|ryP NHzZXGRUSU6JRWK=
LB2518-MEL M4HJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITiTIRKSzVyPUCuNFM4PiEQvF2= NYjsPVV7W0GQR1XS
SH-4 NGKxfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGraRmVKSzVyPUCuNFQ{OSEQvF2= NWLZZ|hIW0GQR1XS
KNS-42 NWewN4dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nPSWlEPTB;MD6wOFQ1OSEQvF2= NVLYVIU1W0GQR1XS
DSH1 NXuwZZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP3U2NKSzVyPUCuNFUzQDlizszN MVXTRW5ITVJ?
NTERA-S-cl-D1 NX;5T5R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjWTWM2OD1yLkC1O|czKM7:TR?= Mny4V2FPT0WU
D-542MG M3H3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfOdGJKSzVyPUCuNFU6PTdizszN MlzaV2FPT0WU
KS-1 NYTzRo1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDifmVKSzVyPUCuNFY1PThizszN MkX5V2FPT0WU
BL-41 NILtOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rt[GlEPTB;MD6wOlk1PyEQvF2= MoXoV2FPT0WU
LXF-289 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrzNZdpUUN3ME2wMlA4ODZ4IN88US=> NYHy[WVmW0GQR1XS
D-247MG M2C4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrRWHNIUUN3ME2wMlA4OjB7IN88US=> M4q1U3NCVkeHUh?=
MMAC-SF NH;teJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jsW2lEPTB;MD6wO|I3QCEQvF2= MWfTRW5ITVJ?
CP66-MEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3eY9EUUN3ME2wMlA4PSEQvF2= NFu5TWVUSU6JRWK=
LB771-HNC NXfQRWp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMEiwN|Yh|ryP MXHTRW5ITVJ?
no-10 NHfReopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO3TYFZUUN3ME2wMlA5QTB7IN88US=> MXfTRW5ITVJ?
A388 NHHKSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEmwOlUh|ryP M2DxOHNCVkeHUh?=
OPM-2 NXGwVGNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjoW3FvUUN3ME2wMlExPDd2IN88US=> NGThWYJUSU6JRWK=
OVCAR-4 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv4TWM2OD1yLkGwPVM5KM7:TR?= NWTYRlJ6W0GQR1XS
HOP-62 NHHxWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMUC5OFkh|ryP NFzvbXdUSU6JRWK=
ML-2 NUPJ[49vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMUG4NFYh|ryP MVjTRW5ITVJ?
UACC-257 M{jSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXYTWM2OD1yLkGxPVI4KM7:TR?= M2PEdHNCVkeHUh?=
NEC8 NFHHdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMUG5PVUh|ryP NH3mOWJUSU6JRWK=
ONS-76 NUj3[md6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL5bmxvUUN3ME2wMlEzQTN3IN88US=> NIDJOXhUSU6JRWK=
KE-37 M1fKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfQZ2xKSzVyPUCuNVMzPzhizszN M4C3O3NCVkeHUh?=
HT-144 NW\rb256T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP1Nm4{UUN3ME2wMlE{QDl3IN88US=> NEjYRnVUSU6JRWK=
LB2241-RCC NGnHPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjmfnlOUUN3ME2wMlE1OjR5IN88US=> MnXyV2FPT0WU
TE-5 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfmT2F4UUN3ME2wMlE1Ojd6IN88US=> M{O3W3NCVkeHUh?=
KINGS-1 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzKeYNKSzVyPUCuNVQ4QSEQvF2= MoLwV2FPT0WU
NCI-H69 M{ji[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XFeWlEPTB;MD6xOVE1OSEQvF2= MVTTRW5ITVJ?
CAS-1 NGTVbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKzTWM2OD1yLkG1OFgzKM7:TR?= M4K1VHNCVkeHUh?=
D-263MG NHHLZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjaXZZRUUN3ME2wMlE3ODB4IN88US=> NFf6[oNUSU6JRWK=
A253 NY\3OWpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrPPIplUUN3ME2wMlE3OTJ6IN88US=> Mnn1V2FPT0WU
PF-382 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\sTWM2OD1yLkG2O|A3KM7:TR?= M2fJT3NCVkeHUh?=
CESS NF7oW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMUewOkDPxE1? NIKxeoRUSU6JRWK=
MZ2-MEL Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrRTWM2OD1yLkG3OVU6KM7:TR?= NEnzd3VUSU6JRWK=
HEL M4fvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TVVmlEPTB;MD6xPFUyPyEQvF2= NXPQWmQxW0GQR1XS
D-392MG NVzLbWhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMUmxNVUh|ryP M{jEe3NCVkeHUh?=
SK-LMS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17QR2lEPTB;MD6xPVMxOyEQvF2= NXXmS2tVW0GQR1XS
GI-ME-N NX\H[25GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr3TWM2OD1yLkG5N|A3KM7:TR?= NYPmV3VbW0GQR1XS
LB831-BLC NFXHRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jOUWlEPTB;MD6xPVM1KM7:TR?= NH\OWohUSU6JRWK=
DU-4475 NXLxfIVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPuZm1wUUN3ME2wMlE6PjV6IN88US=> NXvFUlhqW0GQR1XS
IST-SL1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULWZ|hPUUN3ME2wMlIxODl2IN88US=> MojYV2FPT0WU
GAK M17WcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiyVGZKSzVyPUCuNlA2OzRizszN NWLDenhjW0GQR1XS
EW-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TPW2lEPTB;MD6yNVA1PyEQvF2= M1HnbHNCVkeHUh?=
LAMA-84 M2KyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LQU2lEPTB;MD6yNVg2OSEQvF2= NG[wNINUSU6JRWK=
SK-UT-1 NV[3WFlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mySmlEPTB;MD6yNlA1QSEQvF2= M4DOTHNCVkeHUh?=
VA-ES-BJ M1PycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPrU|lQUUN3ME2wMlIzOjV5IN88US=> NIixOndUSU6JRWK=
ACN NFL6XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMkK2N|gh|ryP M4fOT3NCVkeHUh?=
SK-PN-DW M4TzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[wUGNFUUN3ME2wMlI{OTlizszN M4DkcXNCVkeHUh?=
HD-MY-Z Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTRTndCUUN3ME2wMlI{OzB|IN88US=> NV32NFk1W0GQR1XS
LB373-MEL-D MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HDNWlEPTB;MD6yOFE6QCEQvF2= MnnYV2FPT0WU
COLO-829 NGroUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDDTWM2OD1yLkK0NlU4KM7:TR?= M2PnZnNCVkeHUh?=
ES8 NVy3R2FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3LfYs{UUN3ME2wMlI1PzZ|IN88US=> NUL5b3EyW0GQR1XS
RXF393 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknyTWM2OD1yLkK1NFE2KM7:TR?= NEPzWmRUSU6JRWK=
TK10 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS1TWM2OD1yLkK1OFM2KM7:TR?= MVjTRW5ITVJ?
LOUCY MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMkW0OVYh|ryP MljtV2FPT0WU
MZ7-mel M1nLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHmRnJKSzVyPUCuNlY{PzRizszN NHXjWJhUSU6JRWK=
CP67-MEL NIKxOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnDTWM2OD1yLkK2O|Mh|ryP NVfT[W02W0GQR1XS
C2BBe1 NITWTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj4NnJOUUN3ME2wMlI4QTB5IN88US=> MUXTRW5ITVJ?
K052 NXK4Z41IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L1NmlEPTB;MD6yPFk6KM7:TR?= NFrHbIxUSU6JRWK=
MOLT-16 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3foWmlEPTB;MD6yPVUzPCEQvF2= M4XJU3NCVkeHUh?=
KNS-81-FD NV3SOYJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPhfJBIUUN3ME2wMlMxOzJ|IN88US=> M{DJeHNCVkeHUh?=
CMK MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rnNWlEPTB;MD6zNVEzKM7:TR?= M4TqW3NCVkeHUh?=
LAN-6 MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr1dFBKSzVyPUCuN|E{KM7:TR?= MmD4V2FPT0WU
KLE MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwM{GzNFYh|ryP NH3ZTHJUSU6JRWK=
NCCIT M3LTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\xfmlEPTB;MD6zNVc5OyEQvF2= NWrBTII3W0GQR1XS
HH M2PsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\PUWlEPTB;MD6zNlg6PyEQvF2= M3XXbnNCVkeHUh?=
TE-8 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwM{SyO|kh|ryP MV;TRW5ITVJ?
GDM-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwM{WxNFQh|ryP MmnDV2FPT0WU
NCI-H747 NUn6b5NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPnTWM2OD1yLkO3NVA{KM7:TR?= M2jneXNCVkeHUh?=
NCI-H1092 NYjlWpdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr1TFlKSzVyPUCuN|g5PDRizszN M4PvWHNCVkeHUh?=
8-MG-BA M2HIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwM{m4N|ch|ryP MljoV2FPT0WU
NB17 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PlZ2lEPTB;MD60Nlk4KM7:TR?= NF3IN4hUSU6JRWK=
LC4-1 M2DGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwNEO2NFch|ryP MljoV2FPT0WU
TE-1 NFXM[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwNEWxNVkh|ryP M2fUTHNCVkeHUh?=
KALS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwNE[1PFQh|ryP M1HHVXNCVkeHUh?=
CCRF-CEM M3q2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzqfVU3UUN3ME2wMlQ4Pjd2IN88US=> NVL1S|NoW0GQR1XS
OS-RC-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXyW5pKSzVyPUCuOFc6PzJizszN MnLwV2FPT0WU
A704 NGezZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwNEi2PVIh|ryP NETZeWdUSU6JRWK=
BB49-HNC M3nBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwNEmwPVYh|ryP NYXi[I1kW0GQR1XS
EVSA-T MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXMRYZKSzVyPUCuOFk6OTFizszN M4G5UnNCVkeHUh?=
Mo-T MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLodo9KSzVyPUCuOVE4PjJizszN NYK2So1NW0GQR1XS
MONO-MAC-6 MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jwVmlEPTB;MD61N|YyOSEQvF2= NIi5XY1USU6JRWK=
BB65-RCC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLsTWM2OD1yLkW2PFEyKM7:TR?= NVPNUIhMW0GQR1XS
NCI-H1882 NF\ISWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwNUmwN|Yh|ryP MYjTRW5ITVJ?
TE-9 NELBW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXhTWM2OD1yLk[xNFM{KM7:TR?= MWDTRW5ITVJ?
NCI-H2126 Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwNkK2Olkh|ryP M3HNXHNCVkeHUh?=
SF268 NH\KU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvjTWM2OD1yLk[1OlQyKM7:TR?= NEXFfnpUSU6JRWK=
SW872 NIntWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXlOm85UUN3ME2wMlY2PzJ7IN88US=> NWKybIJUW0GQR1XS
LS-513 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwNk[3OVEh|ryP M4fVNnNCVkeHUh?=
NCI-H1355 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13TbmlEPTB;MD62PFYyQSEQvF2= NGDoXJZUSU6JRWK=
BL-70 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3WTWM2OD1yLk[5N|g5KM7:TR?= MU\TRW5ITVJ?
NCI-SNU-5 M1jLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNkm1OFUh|ryP MV3TRW5ITVJ?
SNU-C2B NGSyT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDzRoxKSzVyPUCuO|A4OzlizszN Mn;TV2FPT0WU
GB-1 NYTTUIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHne|JKSzVyPUCuO|IyOjRizszN NGfuNVlUSU6JRWK=
CTB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfL[YRpUUN3ME2wMlc4QTV3IN88US=> MYTTRW5ITVJ?
Becker NYr2[FFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjZUXhyUUN3ME2wMlc6PjJzIN88US=> NFLKd2xUSU6JRWK=
KM12 NHvlZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvKXmpKSzVyPUCuPFU1PjZizszN NWe5bHFQW0GQR1XS
ES7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwOEm2OUDPxE1? NHLXPYpUSU6JRWK=
COLO-684 NH3EOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\mbXZKSzVyPUCuPVA3PThizszN MXnTRW5ITVJ?
HCC2998 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\jSHhKSzVyPUCuPVM5PTRizszN Mlv6V2FPT0WU
TE-10 NGfXfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwOU[0N{DPxE1? M1PFOHNCVkeHUh?=
SF126 MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn2[2NbUUN3ME2wMlk5QTdzIN88US=> NWr1cYhoW0GQR1XS
EKVX NVHMbFlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nsWmlEPTB;MT6wN|Q1OiEQvF2= MmX5V2FPT0WU
KARPAS-45 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPnSoZKSzVyPUGuNFQxOTZizszN MU\TRW5ITVJ?
KGN MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL1ZWhGUUN3ME2xMlA2ODR3IN88US=> M1jZeHNCVkeHUh?=
ES1 M{HBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDWcmJKSzVyPUGuNFc6OjFizszN M3TBcnNCVkeHUh?=
L-540 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHQTWM2OD1zLkGxPFM6KM7:TR?= NFjlc3pUSU6JRWK=
KURAMOCHI NFm4PIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK5SpNKSzVyPUGuNVI{PzRizszN MY\TRW5ITVJ?
LU-65 NWj1RY1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXhZYxDUUN3ME2xMlEzPzV|IN88US=> M{K1cHNCVkeHUh?=
MFH-ino M{nlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrCTWM2OD1zLkG3OVAyKM7:TR?= MYnTRW5ITVJ?
NCI-H23 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jBU2lEPTB;MT6yNFQyKM7:TR?= NX3wXYNHW0GQR1XS
IA-LM NXHkS4tqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKwTWM2OD1zLkK0NVE3KM7:TR?= NYDh[GNkW0GQR1XS
PSN1 MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PXZ2lEPTB;MT6yO|AyPiEQvF2= M17wS3NCVkeHUh?=
NCI-H719 M3\4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnvZVFuUUN3ME2xMlI4PDFzIN88US=> NEXCUpZUSU6JRWK=
SW684 NHztbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W5dGlEPTB;MT6yPFY2QSEQvF2= NFzTcJdUSU6JRWK=
HCE-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fNfGlEPTB;MT6zNFIzOSEQvF2= NUP6eYFzW0GQR1XS
EW-16 M{fHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwM{GzOFch|ryP MVXTRW5ITVJ?
NCI-H128 M1vibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfObnZKSzVyPUGuN|U5OTRizszN M1GyNXNCVkeHUh?=
HC-1 MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH4OY1KSzVyPUGuN|gyPyEQvF2= NVjWPJhDW0GQR1XS
IST-MES1 NUez[HlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwNECyNFgh|ryP NYLhZ2hvW0GQR1XS
Raji MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwNEG4OUDPxE1? NXHxeolwW0GQR1XS
DMS-114 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfPSXhuUUN3ME2xMlQ1PTN7IN88US=> MmD4V2FPT0WU
GI-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHV[FdKSzVyPUGuOFcyOzFizszN MVPTRW5ITVJ?
NCI-H2081 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH2TWM2OD1zLkW1NVk3KM7:TR?= NILteY1USU6JRWK=
LC-1F M1\1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOwe3hKSzVyPUGuOVUyQThizszN MmG0V2FPT0WU
NCI-H2227 NFj6[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrCZmxKSzVyPUGuOlE2PjFizszN M{TSUHNCVkeHUh?=
D-502MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm5TWM2OD1zLk[3NlEyKM7:TR?= NVHVSFdYW0GQR1XS
NCI-H2141 NYTMOpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PoTmlEPTB;MT62O|MyPyEQvF2= NVjCOGRYW0GQR1XS
LS-411N MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HxbWlEPTB;MT62PVgxPyEQvF2= NXTvVGlbW0GQR1XS
SU-DHL-1 NIW1b4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjtTZh1UUN3ME2xMlcyOjhzIN88US=> NGPpZ2ZUSU6JRWK=
BB30-HNC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOzWZdrUUN3ME2xMlczPjh3IN88US=> NWH2Z446W0GQR1XS
TE-15 NFnCVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T2PWlEPTB;MT65NlM4OyEQvF2= NHmzfWpUSU6JRWK=
JVM-3 M4\jOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TDSmlEPTB;MT65N|kxPCEQvF2= NYL3blVCW0GQR1XS
IST-SL2 NGHudFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX4ZlBKSzVyPUKuNFEzPTJizszN MUTTRW5ITVJ?
EW-18 NHPvWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC0TWM2OD1{LkCyN|M4KM7:TR?= NIDOVnRUSU6JRWK=
DJM-1 NFPBZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fG[mlEPTB;Mj6wNlU2OiEQvF2= M2TVTXNCVkeHUh?=
no-11 NEPv[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\WNZBKSzVyPUKuNFMyODRizszN NETLT2pUSU6JRWK=
QIMR-WIL NVjJc4loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHyTWM2OD1{LkG2O|YzKM7:TR?= NEfi[pVUSU6JRWK=
MC-CAR MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwMkK5OUDPxE1? MlTEV2FPT0WU
KM-H2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfm[XJbUUN3ME2yMlI6ODR|IN88US=> NW[5XJduW0GQR1XS
ECC12 NUn0bGJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJwM{e5OEDPxE1? MWnTRW5ITVJ?
HCE-T NIPFdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7JTWM2OD1{LkS0PFg{KM7:TR?= NE\OTpNUSU6JRWK=
MFM-223 NYj5eItGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jBXWlEPTB;Mj61NFg4OSEQvF2= M3;XcHNCVkeHUh?=
SW982 NWC4PHR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zWdmlEPTB;Mj61NVQ5KM7:TR?= NHXESnVUSU6JRWK=
KG-1 NWDBW|Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;rWnVKSzVyPUKuPFg4QTFizszN MVTTRW5ITVJ?
ES4 NXTsSnpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XNbmlEPTB;Mz6wOlEyOSEQvF2= NYXjW5B5W0GQR1XS
SCC-3 M4GzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PFWWlEPTB;Mz6xNFg1QCEQvF2= MWLTRW5ITVJ?
RH-1 NXfDV2dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNwM{i3OFgh|ryP NHzDeXRUSU6JRWK=
NCI-H748 M{XoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf1TWM2OD1|LkS0NlY3KM7:TR?= NYDHWVZjW0GQR1XS
HCC2218 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTNwNE[5N|ch|ryP NH;vNG5USU6JRWK=
MEG-01 NIG3ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\4c4RKSzVyPUOuOVk3QCEQvF2= NHHUZ|ZUSU6JRWK=
NB12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqyfVdKSzVyPUOuOVk5QDhizszN NH[zWnRUSU6JRWK=
SNB75 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;STWM2OD1|Lk[wNVA{KM7:TR?= MYjTRW5ITVJ?
KMS-12-PE NWKxTXhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHxTWM2OD1|Lk[3O|I{KM7:TR?= MmqzV2FPT0WU
SKM-1 M2Lj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fiNWlEPTB;Mz63NVM4PiEQvF2= MUnTRW5ITVJ?
COLO-320-HSR Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHiOGlKSzVyPUOuO|U3OzRizszN NU\XcmhLW0GQR1XS
NKM-1 M2S4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP0bWRyUUN3ME2zMlc4Ozd6IN88US=> MUjTRW5ITVJ?
TE-6 M1;4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLtR3BHUUN3ME2zMlk1PTZzIN88US=> MUDTRW5ITVJ?
D-336MG NFrJ[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrITWM2OD12LkCxNVY3KM7:TR?= NF[3cYhUSU6JRWK=
NCI-H1650 M2DyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6zPYxtUUN3ME20MlE2Pzl5IN88US=> MkjSV2FPT0WU
ES3 NF\6ZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTRwM{K4NlQh|ryP MX3TRW5ITVJ?
YT NXrKU25GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwM{W0NlQh|ryP MX\TRW5ITVJ?
ES5 M3;lTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHGXFJVUUN3ME20MlQxOjV3IN88US=> M1\KTHNCVkeHUh?=
LB647-SCLC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS5TWM2OD12LkW2N|A5KM7:TR?= MYDTRW5ITVJ?
HAL-01 M{LOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f5fWlEPTB;ND61O|A{PCEQvF2= NHzJUWZUSU6JRWK=
LP-1 NFTvXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr5OlVKSzVyPUSuO|I{PzFizszN NVS2WHpRW0GQR1XS
BC-1 M3rpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiy[mxKSzVyPUWuNFA1PDdizszN NELHTZRUSU6JRWK=
EB-3 NUfRSJZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfMdY1RUUN3ME21MlA{ODRzIN88US=> MnXTV2FPT0WU
GT3TKB M3fyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWyTWM2OD13LkG3OlYzKM7:TR?= MUHTRW5ITVJ?
NCI-H209 NIfZbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n4UGlEPTB;NT6xPVM2OiEQvF2= MnvGV2FPT0WU
BT-474 M164Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\wdZpKSzVyPUWuNlMyODJizszN NE\YNFhUSU6JRWK=
RKO M3jhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2foRWlEPTB;NT6yN|QzOiEQvF2= NYLhPIppW0GQR1XS
SIMA Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfiTWM2OD13LkOwO|Y2KM7:TR?= Mn:1V2FPT0WU
RL M2XoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjJTWM2OD13LkO3OVQyKM7:TR?= MUPTRW5ITVJ?
GCIY M3HkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTVwNEeyN|Yh|ryP MVfTRW5ITVJ?
Calu-6 M3zDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37qNGlEPTB;NT62NlIh|ryP NXX2cYJnW0GQR1XS
ALL-PO M2qyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTVwNkO3PVUh|ryP NGTnO|lUSU6JRWK=
ARH-77 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTVwNkewPFch|ryP MlT6V2FPT0WU
A4-Fuk NFn3W5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXEdmJKSzVyPU[uNFgyOThizszN NIfBZmJUSU6JRWK=
NCI-H1581 NUfWSIpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\0PWlEPTB;Nj6yN|g1QSEQvF2= NVK5OIp1W0GQR1XS
HUTU-80 NV\xTYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj5TWM2OD14LkO2PFk4KM7:TR?= MlPhV2FPT0WU
TGW NX\hWHBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ztPWlEPTB;Nj60OVU6OyEQvF2= MXXTRW5ITVJ?
SK-N-FI MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTZwNEW4OVQh|ryP M1nHOHNCVkeHUh?=
U-266 NEXtW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXITWM2OD14LkWxPVI3KM7:TR?= NYXYSpJMW0GQR1XS
EM-2 M1nkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTZwNkewPVkh|ryP NVnXVplnW0GQR1XS
NMC-G1 NGrqNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGwZoxKSzVyPU[uO|E5QTVizszN Mk\wV2FPT0WU
KASUMI-1 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\VXIlKSzVyPU[uPFQ4QDdizszN MYLTRW5ITVJ?
NALM-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe1fHpKSzVyPU[uPFY4PTRizszN NHXlNHpUSU6JRWK=
OCI-AML2 NGPSUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX3bYhKSzVyPUeuNFA{OjZizszN MUjTRW5ITVJ?
SHP-77 NYjZToFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTdwMkK0N{DPxE1? Ml7mV2FPT0WU
NOMO-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrDN|FKSzVyPUeuNlQzPTRizszN MoLrV2FPT0WU
SK-N-DZ NEG5b4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXxeFNKSzVyPUeuO|ExQDlizszN Mn\SV2FPT0WU
LB1047-RCC Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm1RoE6UUN3ME23MlczOjNzIN88US=> MknwV2FPT0WU
MZ1-PC Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\3TWM2OD15Lki2OVU5KM7:TR?= MWHTRW5ITVJ?
NB10 M1TFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nvOmlEPTB;Nz65PVU2PiEQvF2= MVLTRW5ITVJ?
RL95-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTQTWM2OD16LkGwPFQzKM7:TR?= M3fwUHNCVkeHUh?=
OMC-1 NWHicpZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj5TWM2OD16LkWyNVkyKM7:TR?= M{fhe3NCVkeHUh?=
D-283MED Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfDN5JPUUN3ME24MlkyPzF7IN88US=> MXrTRW5ITVJ?
MC116 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLEfG5KSzVyPUiuPVc6PCEQvF2= NEDOOFBUSU6JRWK=
SJSA-1 NUnpd3BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL5SnVbUUN3ME25MlA6ODlzIN88US=> MWDTRW5ITVJ?
JiyoyeP-2003 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHRXodKSzVyPUmuNlk{OTdizszN NFrCeWRUSU6JRWK=
IST-MEL1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\nb2lEPTB;OT63OFE6QCEQvF2= NV73S2xDW0GQR1XS
CTV-1 NXvNbmUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFyLkC5O|kh|ryP MYrTRW5ITVJ?
NH-12 NUm0OlJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFyLkK0N|Mh|ryP MoX0V2FPT0WU
CA46 NGHSXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3SWlEPTB;MUCuN|YyKM7:TR?= NV3hdYw5W0GQR1XS
NCI-SNU-1 NUDWNVdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFyLkS5Olkh|ryP MmnpV2FPT0WU
SCLC-21H MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XSbGlEPTB;MUCuOlU6PiEQvF2= MoLNV2FPT0WU
EC-GI-10 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFyLkewN|Eh|ryP NYDhbHBbW0GQR1XS
SR NHq1c3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfQO3FKSzVyPUGxMlAyQDVizszN MorHV2FPT0WU
NCI-H1648 NX;RWlRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGxV2tKSzVyPUGxMlA6PjVizszN NGHa[4VUSU6JRWK=
TGBC1TKB M37ROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu5TWM2OD1zMT60NVAzKM7:TR?= NF73WYlUSU6JRWK=
EW-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPWbGZKSzVyPUGxMlUyQDZizszN MXrTRW5ITVJ?
SK-MM-2 NU\mPFV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XYd2lEPTB;MUGuPFA3OSEQvF2= NFqzeo5USU6JRWK=
NCI-H524 NVXVOIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUewXJg2UUN3ME2xNU46QDJ{IN88US=> MoLBV2FPT0WU
NOS-1 NF\vWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTIWmxKSzVyPUGyMlA{PDVizszN NIDDdWtUSU6JRWK=
AM-38 M1Pkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF{LkW2N|Mh|ryP Mm\iV2FPT0WU
A498 M4Ttd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF{LkewOlkh|ryP NYS0SHBwW0GQR1XS
KARPAS-422 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF{Lke0PVYh|ryP Mly0V2FPT0WU
LU-139 NGDpOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF{LkmwNlYh|ryP NEniOGNUSU6JRWK=
COR-L88 NXnhb2JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnJWXRJUUN3ME2xNk46Ozh{IN88US=> MWXTRW5ITVJ?
K5 NUXyNYl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu2TWM2OD1zMj65OFYzKM7:TR?= MnzaV2FPT0WU
NB13 NELSbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\SUFB7UUN3ME2xNk46Pzh|IN88US=> NIC0XopUSU6JRWK=
MRK-nu-1 NV;UU5FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK5T4huUUN3ME2xN{4yQTVizszN M4XyZXNCVkeHUh?=
MHH-NB-11 MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHXTWM2OD1zMz6yPVAzKM7:TR?= NInkSYlUSU6JRWK=
KU812 M2\1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF|Lk[xNlQh|ryP NWXuNpJIW0GQR1XS
TE-12 M3r6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF|Lk[5PVQh|ryP MVzTRW5ITVJ?
NCI-N87 NUjlSo5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz2TWM2OD1zMz63N|Yh|ryP NUPVT3F7W0GQR1XS
EB2 M2TrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF|Lki1NFUh|ryP MXrTRW5ITVJ?
DB MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli3TWM2OD1zMz65PFg2KM7:TR?= MU\TRW5ITVJ?
697 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnuxTWM2OD1zND60OVEyKM7:TR?= NV7EVZF1W0GQR1XS
MSTO-211H M3LYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDxTWM2OD1zND63OFQ5KM7:TR?= M1vvOHNCVkeHUh?=
JVM-2 NFvseVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HvZmlEPTB;MUSuO|c{PSEQvF2= NHfR[pNUSU6JRWK=
COLO-824 NWLPbVJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:1epo6UUN3ME2xOE44QTl2IN88US=> M1vGW3NCVkeHUh?=
BC-3 M3vpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13zUWlEPTB;MUWuN|k5KM7:TR?= MVvTRW5ITVJ?
BOKU M3myNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q2NmlEPTB;MUWuPVYxQCEQvF2= MV3TRW5ITVJ?
GOTO MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;6TWM2OD1zNj65OlE4KM7:TR?= MWnTRW5ITVJ?
HCC2157 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF5LkS3OVUh|ryP NV:1OmJOW0GQR1XS
LS-1034 MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X4fWlEPTB;MUeuOlgyQCEQvF2= M2PrNnNCVkeHUh?=
CAL-148 M4LiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTiTGtKSzVyPUG3Mlk4QTZizszN NXvBSYdoW0GQR1XS
MOLT-4 NF;ZSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLz[nBxUUN3ME2xPE45OjB6IN88US=> NX;zNndwW0GQR1XS
Daudi MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF6LkmyN|Eh|ryP MojSV2FPT0WU
J-RT3-T3-5 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP1TWM2OD1zOT60NFY3KM7:TR?= NYDzeGxwW0GQR1XS
KMOE-2 NEfMNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETzOWRKSzVyPUG5MlY1QDJizszN MmHoV2FPT0WU
HL-60 NFf5V|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17mc2lEPTB;MkCuNVk3PSEQvF2= MYfTRW5ITVJ?
P31-FUJ NFzsRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7FSVF1UUN3ME2yNE41PzV|IN88US=> MVnTRW5ITVJ?
IM-9 NGDhS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj6VmpKSzVyPUKwMlYzOjRizszN NX3qOXJsW0GQR1XS
HDLM-2 MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWxTWM2OD1{MD64PFIyKM7:TR?= MlHsV2FPT0WU
NCI-H1304 M3HsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe3WGdUUUN3ME2yNU4xOzFzIN88US=> NFTsV3RUSU6JRWK=
NCI-H345 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r2XGlEPTB;MkGuNFY1OyEQvF2= NVrEUmtwW0GQR1XS
RPMI-6666 NHPmUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\h[GlEPTB;MkGuN|YxOiEQvF2= NGq5XlVUSU6JRWK=
GR-ST NGTEU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTmTWM2OD1{MT60NVch|ryP M1ztRnNCVkeHUh?=
CHP-126 M17JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2GxSGlEPTB;MkGuOlE5OSEQvF2= MV;TRW5ITVJ?
EHEB NYf3e4lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJzLk[3N|Eh|ryP Mln6V2FPT0WU
CPC-N NVjzPI1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKze2FKSzVyPUK0MlAzODFizszN NXv3e3RjW0GQR1XS
NB1 NHzqVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVztWHlWUUN3ME2yOE43QTN7IN88US=> MlPqV2FPT0WU
LS-123 M1X5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ2LkmwNVIh|ryP Mn;NV2FPT0WU
ST486 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTCNldKSzVyPUK1MlEyOTNizszN MXLTRW5ITVJ?
NCI-H1963 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HKOmlEPTB;Mk[uNFYzOyEQvF2= NYXIcYlbW0GQR1XS
U-87-MG Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXGbm5PUUN3ME2yOk44PjR2IN88US=> MVfTRW5ITVJ?
COR-L279 Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvkR5hKSzVyPUK2Mlc6OjJizszN M4[3O3NCVkeHUh?=
LU-165 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrDTWM2OD1{OD6wPFYyKM7:TR?= NHHINI5USU6JRWK=
COLO-800 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXXTWM2OD1{OD6yPVU3KM7:TR?= NY\RN2JyW0GQR1XS
ETK-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT3RnFKSzVyPUK4MlM1PDZizszN MX;TRW5ITVJ?
LNCaP-Clone-FGC MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ7LkmyPFEh|ryP MUPTRW5ITVJ?
SIG-M5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHuTWM2OD1|MD63PVUzKM7:TR?= MX3TRW5ITVJ?
NB6 NUi1TGt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTNyLkm1NFMh|ryP MXnTRW5ITVJ?
NCI-H2107 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P1NGlEPTB;M{GuNlM{QCEQvF2= MmrMV2FPT0WU
SNU-C1 M2TTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTNzLkOxNlYh|ryP M2DheXNCVkeHUh?=
JAR MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNzLkO3PVkh|ryP MU\TRW5ITVJ?
L-363 MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37zOGlEPTB;M{KuNlE1PCEQvF2= M1vONXNCVkeHUh?=
EW-24 M{HH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fZcGlEPTB;M{KuN|Q4PCEQvF2= MUPTRW5ITVJ?
NB69 NVvkZ|FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXWTWM2OD1|Mz62OFU1KM7:TR?= NXO3RnhXW0GQR1XS
EW-13 M{DDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvuPGxKSzVyPUOzMlg6PjlizszN MmPDV2FPT0WU
Ramos-2G6-4C10 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\XVWlEPTB;M{SuNlk6OyEQvF2= NFXIN3BUSU6JRWK=
TE-11 NEDkXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN2LkS4NlIh|ryP M4nHVHNCVkeHUh?=
L-428 NFPMZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;K[HJKSzVyPUO0Mlc2OzZizszN MmTsV2FPT0WU
KP-N-YN M3LJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW4TWM2OD1|ND65NFU4KM7:TR?= NXHTOXBzW0GQR1XS
CGTH-W-1 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF2zfpNKSzVyPUO2MlkxPDhizszN Mkm2V2FPT0WU
K-562 M{HpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\STWM2OD1|Nz6wPFY1KM7:TR?= NUexe|NmW0GQR1XS
NCI-H1299 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljMTWM2OD1|OD6xOlA{KM7:TR?= MoHlV2FPT0WU
RCC10RGB NVXicHpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\BTWM2OD1|OD6yNFg{KM7:TR?= NIDCRZhUSU6JRWK=
NCI-SNU-16 MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C3bGlEPTB;M{iuOVY2OyEQvF2= NWrTNmtNW0GQR1XS
LC-2-ad MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vnRWlEPTB;M{muOFM{PyEQvF2= MoPvV2FPT0WU
MHH-PREB-1 NIfYe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nSWWlEPTB;M{muO|M5QCEQvF2= MUDTRW5ITVJ?
NCI-H64 NH3qdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO2bo5KSzVyPUSwMlA6PDhizszN M{fKVXNCVkeHUh?=
LB996-RCC M1e0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjzS4FKSzVyPUSwMlg4OTZizszN M3nPV3NCVkeHUh?=
DEL M3fhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDtS3EyUUN3ME20NU41PDB3IN88US=> NIDOOnVUSU6JRWK=
MLMA NYTDVnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTRzLke1PVUh|ryP MX7TRW5ITVJ?
SBC-1 NGKxVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fJWWlEPTB;NEKuNVgxPiEQvF2= Mk\4V2FPT0WU
MPP-89 NIDJVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:wOWlEPTB;NEKuOVg4PSEQvF2= MlXOV2FPT0WU
MV-4-11 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR{LkmwOlch|ryP MXXTRW5ITVJ?
EoL-1- MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTR2LkG1Olgh|ryP NV76W|hPW0GQR1XS
CW-2 NFjK[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknETWM2OD12ND64N|QzKM7:TR?= NIT1SWJUSU6JRWK=
HT NFG0VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTR3LkewNFch|ryP M2L6R3NCVkeHUh?=
SW954 NXHYSXlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;jTWM2OD12Nz60NVI5KM7:TR?= MVrTRW5ITVJ?
A3-KAW M4H2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j1RmlEPTB;NEmuPFA3OSEQvF2= M1i4U3NCVkeHUh?=
TC-YIK MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HVZWlEPTB;NUCuNFM3OyEQvF2= NW[3OZU4W0GQR1XS
SW962 M2XoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL3fWtKSzVyPUW0Mlg{PTdizszN MkDzV2FPT0WU
KP-N-RT-BM-1 NG\jSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Wx[GlEPTB;NU[uOlY{QCEQvF2= Ml\EV2FPT0WU
NCI-H1395 NGLuOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTV6LkixO|Ih|ryP NHnOSFdUSU6JRWK=
RPMI-8402 NVzRcGV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnOTWM2OD13OD65OVI3KM7:TR?= Ml\xV2FPT0WU
SCH NVfQNlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;OTWM2OD14MD65OlM5KM7:TR?= MlvFV2FPT0WU
NCI-H2196 NH31XW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPtUYtKSzVyPU[xMlI{OSEQvF2= Mn\QV2FPT0WU
LOXIMVI NEjDPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojaTWM2OD14MT64NlY3KM7:TR?= MXPTRW5ITVJ?
TGBC24TKB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rmemlEPTB;NkKuNVQ6OSEQvF2= M{H3bnNCVkeHUh?=
SK-MEL-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T4b2lEPTB;NkOuPVg6OiEQvF2= M123cnNCVkeHUh?=
U-698-M NVLGfZozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3kTWM2OD14OD61Olg4KM7:TR?= MVXTRW5ITVJ?
NCI-H1522 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTZ7LkCwOFch|ryP NEfERo9USU6JRWK=
UACC-812 M4DNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnCTWM2OD14OT61NlA6KM7:TR?= MV7TRW5ITVJ?
MHH-CALL-2 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPkTWM2OD15MD6wOkDPxE1? NYHjfm11W0GQR1XS
NB5 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTdyLkO0Olgh|ryP MYLTRW5ITVJ?
KARPAS-299 NXPyOXFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTpTWM2OD15MD60OFQ4KM7:TR?= MmDIV2FPT0WU
NCI-H1694 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTdzLkCzNkDPxE1? NUPFN5o2W0GQR1XS
NCI-H82 NWrEPJY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HWOWlEPTB;N{GuPVUxPyEQvF2= MYfTRW5ITVJ?
SCC-15 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTd{LkO0JO69VQ>? NVjtNpRuW0GQR1XS
NCI-H1436 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\3dZVKSzVyPUeyMlc1PTZizszN MmHtV2FPT0WU
ATN-1 NEewfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CzRmlEPTB;N{SuOVA2KM7:TR?= Mn;OV2FPT0WU
RPMI-8866 NYrWS4N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fqRWlEPTB;N{SuO|UxQSEQvF2= MXPTRW5ITVJ?
HCC1599 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTd2Lki3N|Ih|ryP NHvuZoVUSU6JRWK=
NCI-H1155 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zhOGlEPTB;N{SuPVM3PyEQvF2= MU\TRW5ITVJ?
DOHH-2 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PBUGlEPTB;N{SuPVUyPCEQvF2= NHL1e2pUSU6JRWK=
SK-NEP-1 NYP4U|F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mye2lEPTB;N{WuNFc2PCEQvF2= NFe1WYNUSU6JRWK=
HCC1187 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\HVWlEPTB;N{euOlEzOiEQvF2= M2LkXXNCVkeHUh?=
NCI-H322M NVH5OXFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDyTWM2OD15OD6zO|A6KM7:TR?= MWDTRW5ITVJ?
NCI-H526 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPq[FVKSzVyPUe4MlU5PzdizszN NX3EVItYW0GQR1XS
NCI-H2171 NXXQToR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS2TWM2OD15OT60NVM3KM7:TR?= MXjTRW5ITVJ?
COLO-668 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnaN4NKSzVyPUixMlU5QDRizszN MV\TRW5ITVJ?
RS4-11 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnVXVJ2UUN3ME24Nk4zPTB3IN88US=> M2iwSHNCVkeHUh?=
NCI-H716 M1TV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL3NGNKSzVyPUiyMlkxPzVizszN M3LlW3NCVkeHUh?=
LU-134-A NEXpVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTh|LkGzOVEh|ryP MmTKV2FPT0WU
RPMI-8226 MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;SbWlEPTB;OESuNlExPyEQvF2= NWDNcJduW0GQR1XS
KY821 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXwdoNoUUN3ME25NU43PTVzIN88US=> NY[0[WdCW0GQR1XS
ECC4 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[yeJFKSzVyPUmzMlgzPjlizszN MVTTRW5ITVJ?
EW-3 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HDfGlEPTB;OUSuPVA5OSEQvF2= M3zwenNCVkeHUh?=
NB7 NGPQT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TqcmlEPTB;OUWuO|c5PiEQvF2= NVjOPFM{W0GQR1XS
NCI-H720 NF7yW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTl6LkSwOlEh|ryP NUDkeWtxW0GQR1XS
NCI-H446 M4\1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTl7Lke1PFgh|ryP M{nDNHNCVkeHUh?=
NCI-H889 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX4R|Z6UUN3ME2xNFQvOjR{IN88US=> NEjDUoJUSU6JRWK=
EW-22 NV35bZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDXco1KSzVyPUGwOk4yQSEQvF2= MV7TRW5ITVJ?
BV-173 NEf3fYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjUTWM2OD1zMEiuO|I5KM7:TR?= MnH3V2FPT0WU
WSU-NHL NGTUTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFyOT62O|Eh|ryP MYHTRW5ITVJ?
MN-60 NH\4dYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqxTWM2OD1zMEmuOlkh|ryP MWrTRW5ITVJ?
DG-75 M3mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT2VpJLUUN3ME2xNVMvOzV{IN88US=> Mlf3V2FPT0WU
DMS-79 MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLXWnZKSzVyPUGxO{4{QDJizszN NYPS[XhUW0GQR1XS
SK-MEL-1 NFPkc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j4VGlEPTB;MUG4MlAxQSEQvF2= M3P1Z3NCVkeHUh?=
DMS-153 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF{MT63OFUh|ryP NH7XW|FUSU6JRWK=
NCI-H510A NH\ZTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P0T2lEPTB;MUK3MlMzKM7:TR?= MUDTRW5ITVJ?
BE-13 NXPl[Y9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLTTWM2OD1zM{SuNFQ1KM7:TR?= M3vUOXNCVkeHUh?=
KP-N-YS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvrT5lKSzVyPUGzPU44OzZizszN Ml32V2FPT0WU
SUP-T1 NVjqWY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDqU3hKSzVyPUG0N{44ODhizszN MXXTRW5ITVJ?
EW-12 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuxUW9MUUN3ME2xOFQvPjl7IN88US=> M3jCWnNCVkeHUh?=
NB14 MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWyTWM2OD1zNEeuNFgzKM7:TR?= NF\yW49USU6JRWK=
MDA-MB-134-VI NIrzXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TQfWlEPTB;MUS4MlI3QCEQvF2= NFnqb|lUSU6JRWK=
NCI-H1770 M2nYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljaTWM2OD1zNU[uNlc6KM7:TR?= MVPTRW5ITVJ?
TUR M{\V[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:3WWlEPTB;MU[3Mlg4KM7:TR?= MULTRW5ITVJ?
NCI-H1417 NHHVUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITh[5NKSzVyPUG4NE4{OzFizszN M3;CeXNCVkeHUh?=
IMR-5 M{LDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF6MT61O|Eh|ryP M2iyOXNCVkeHUh?=
NCI-H226 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF6OD64OlYh|ryP NHHTb5ZUSU6JRWK=
NCI-H187 NHPoRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF7MD6wOlQh|ryP NY[4NopEW0GQR1XS
SF539 NULVe215T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:3RmlEPTB;MUmyMlczQCEQvF2= M{nje3NCVkeHUh?=
TALL-1 Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjZTWM2OD1zOUiuN|A1KM7:TR?= MXjTRW5ITVJ?
TE-441-T MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzMTWM2OD1zOUmuO|M6KM7:TR?= NULNcoNYW0GQR1XS
REH MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ|Nj62NlYh|ryP NWSxTW1LW0GQR1XS
MS-1 NEPPZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fZWmlEPTB;MkO5MlEzOSEQvF2= NUTvbnA3W0GQR1XS
THP-1 NUPY[5FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ4ND63N|gh|ryP MYTTRW5ITVJ?
NCI-H1838 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3nSZdlUUN3ME2yO|EvPDV4IN88US=> MkLiV2FPT0WU
P30-OHK NEHke4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ6Mz64OFch|ryP MnzIV2FPT0WU
C8166 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFju[IpKSzVyPUO0OU4{OzhizszN NYnpTldbW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

細胞アッセイ:

[3]

細胞株 KIM-2, HC11, and ES
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 24, and 48 hours
実験の流れ

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

動物実験:

[7]

動物モデル Male mdx (C57BL/10ScSn DMD mdx) mice
製剤 Dissolved in DMSO, and diluted in PBS
投薬量 ~10 μg/kg/day
投与方法 Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download MG-132 SDF
分子量 475.62
化学式

C26H41N3O5

CAS No. 133407-82-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
エタノール 95 mg/mL (199.73 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

カスタマーフィードバック (9)


Click to enlarge
Rating
Source Nat Cell Biol, 2015, 17(1), 95-103. MG-132 purchased from Selleck
Method Immunoprecipitation
Cell Lines MDA-MB-231 cells
Concentrations 10 uM
Incubation Time 6 h
Results SIAH2 destabilizes LATS2 through proteasome. SIAH2-mediated LATS2 degradation was inhibited by proteasomal inhibitor MG132, but not by lysosomal inhibitor BA-1. The half-life of LATS2 was shortened by SIAH2.

Click to enlarge
Rating
Source Nucleic Acids Res, 2014, 42(1), 458-74. MG-132 purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results As RMND5A downregulation resulted in a rapid decrease of protein Exportin-5, this effect was partially abolished by the proteasome inhibitor MG132, indicating that RMND5A protect Exportin-5 protein against proteasome degradation.

Click to enlarge
Rating
Source Nucleic Acids Res, 2014, 42(1), 458-74. MG-132 purchased from Selleck
Method Immunocytochemistry
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results It was surprised to observe that Exportin-5 retention in nucleus when its protein levels were downregulated by RMND5A siRNA or miR-138. The proteasome inhibitor MG132 could recover not only Exportin-5 protein levels but also its normal subcellular localization.

Click to enlarge
Rating
Source EMBO Mol Med, 2013, 5, 397-412. MG-132 purchased from Selleck
Method Western Blot
Cell Lines MEF cells
Concentrations 30 uM
Incubation Time 6 h
Results Treatment of MEF with proteasome inhibitor MG132 resulted in similar increase of steady state levels of intracellular ATZ in both GFP- and TFEB- transfected Cells.

Click to enlarge
Rating
Source Cell Rep, 2015, 11(9), 1458-73. MG-132 purchased from Selleck
Method Western Blot
Cell Lines A375, Lu1205 cells
Concentrations 5 uM
Incubation Time 10 h
Results MG132 treatment increased JAK1 steady-state levels, masking the effect of RNF125 depletion and partially blocking deregulated JAK1 expression by ectopically expressed RNF125.

Click to enlarge
Rating
Source Plant Physiol, 2012, 60(1), 118-34. MG-132 purchased from Selleck
Method Immunoblot analysis
Cell Lines Arabidopsis thaliana
Concentrations 100 uM
Incubation Time 12 h
Results These rates of loss were markedly slower in the lrb1-1 lrb2-1 background. Importantly, phyB breakdown was also substantially attenuated upon exposing wild-type seedlings to the proteasome inhibitor MG132, thus implicating the 26S proteasome in particular. MG132 treatment also slightly stabilized phyB levels in lrb1-1 lrb2-1 seedlings, implying that other factors besides LRB1 and LRB2 might also direct phyB breakdown.

Click to enlarge
Rating
Source Toxicol Appl Pharmacol, 2015, 286(2), 135-41. MG-132 purchased from Selleck
Method Immunofluorescence
Cell Lines γ-H2AX-stained cells
Concentrations 100 uM
Incubation Time 3 h
Results G2 cell cycle arrest usually reflects the formation of genomic damage in the preceding S-phase, which activates checkpoint response upon the entry of cells into G2 phase. Furthermore, MG132-treated cells also had larger amounts of γ-H2AX, as evidenced by the increased staining in individual nuclei .

Click to enlarge
Rating
Source FEBS Lett, 2012, 586, 3787–3792. MG-132 purchased from Selleck
Method Western Blot
Cell Lines Hela cells
Concentrations
Incubation Time 12 h
Results When GSK-3 (Ser9) degradation was blocked by proteasome inhibitor (MG132), the increased amount of phosphorylated GSK-3 (Ser9) in responding to NOK was more clearly observed in the HeLa-NOK-HA cells (Fig. C).

Click to enlarge
Rating
Source 2012, Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 25 μM
Incubation Time 1-4 h
Results By adding MG132, a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment.

文献中の引用 (42)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related プロテアソーム 阻害剤

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516)が、幅広いスペクトルマトリックス・メタロプロテアーゼ(MMP) MMP-9、MMP-1、MMP-2、MMP-14とMMP-7のための阻害剤です。

  • Ledipasvir (GS5885)

    Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

  • Bortezomib (PS-341)

    Bortezomib (PS-341)は、強力なプロテアソーム阻害剤で、Kiが0.6nMです。

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is a proteasome inhibitor with IC50 less than 5 nM.

  • Ixazomib (MLN2238)

    Ixazomib (MLN2238)は窒素端加帽の二ペプチドロイシンホウ酸で、20Sプロテアソームのカイモトリプシン類(β5)加水分解部位を抑制、IC50が3.4nM、Ki値が0.93nM。

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914(PR-957)は、恒常的プロテアソームのための最小限の交差反応性を持つ強力かつ選択的な免疫プロテアソームの阻害剤です。

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708は二代目経口生物の有効性にプロテアソーム選択阻害剤で、20Sプロテアソームのカイモトリプシン類(β5)加水分解部位に作用すると、IC50が3.4nM、Ki値が0.93nMになる。

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

最近チェックしたアイテム

Tags: MG-132を買う | MG-132供給者 | MG-132を購入する | MG-132費用 | MG-132生産者 | オーダーMG-132 | MG-132代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ